logo

Clinical Trial Calendar

Share
Results Date
Company Name
Ticker
Event
Indication
Outcome
Details
Q4 2018
Tesaro Inc.
Submission of sNDA seeking label expansion for ZEJULA
Maintenance treatment of patients with recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer
Q4 2018
SAGE Therapeutics, Inc.
Top-line data from placebo-controlled pivotal trial of SAGE-217
Postpartum Depression
Q4 2018
Foamix Pharmaceuticals Ltd.
Top-line result from Phase 3 clinical study of FMX103 (FX2016-11)
Moderate-to-severe papulopustular rosacea
Q4 2018
Foamix Pharmaceuticals Ltd.
Top-line result from Phase 3 clinical study of FMX103 (FX2016-12)
Moderate-to-severe papulopustular rosacea
Q4 2018
Endocyte, Inc.
Submission of IND for EC17/CAR T-cell therapy
Osteosarcoma
Q4 2018
Arbutus Biopharma Corp.
Interim 6-week results from ongoing phase II study of ARB-1467 in combination with tenofovir (TDF), and pegylated interferon
Chronic Hepatitis B Virus (HBV)
01-Sep-2018 To 30-Nov-2018
Mirati Therapeutics, Inc.
Update from phase II study of Sitravatinib in combination with Opdivo
Non-small cell lung cancer
01-Sep-2018 To 30-Nov-2018
Mirati Therapeutics, Inc.
Update from phase Ib study of Sitravatinib as a single agent
Non-small cell lung cancer
after Q4 2018
Celsion Corp.
Clinical findings from Phase I cohort of 12 patients of Phase I/II randomized clinical trial of GEN-1 (OVATION II )
Localized treatment of ovarian cancer
01-Sep-2018 To 30-Nov-2018
Mirati Therapeutics, Inc.
Update from phase II study of Mocetinostat
Non-small cell lung cancer
after Q4 2018
BeyondSpring Inc.
Topline Phase 2 data for Study 106 evaluating Plinabulin + TAC (Taxotere/Adriamycin/cyclophosphamide)
Chemotherapy-induced neutropenia (CIN)
after Q4 2018
BeyondSpring Inc.
Submission of NDA for Plinabulin
Chemotherapy-induced neutropenia (CIN)
Sep 2018
Esperion Therapeutics
Top-line results from the pivotal Phase 3 Study 2 (1002-047) of bempedoic acid
ASCVD patients on maximally tolerated statin background therapy
after Q4 2018
Sarepta Therapeutics
60-day biopsy data from Phase 1/2a study of MYO-101
LGMD2E (beta-sarcoglycanopathy)
after Q4 2018
Xenetic Biosciences, Inc.
Interim data from phase II clinical study of XBIO-101 in conjunction with progestin therapy
Endometrial cancer
after Q4 2018
Ophthotech Corp.
Initial top-line data from phase 2a clinical trial of Zimura
Wet age-related macular degeneration
after Q4 2018
Nymox Pharmaceutical Corporation
Submission of NDA for Fexapotide Triflutate
Benign prostatic hyperplasia
after Q4 2018
SteadyMed Ltd.
Resubmission of Trevyent NDA
Pulmonary Arterial Hypertension
after Q4 2018
Regenxbio Inc
Topline data from RGX-314 Phase I clinical trial
wet age-related macular degeneration (wet AMD)
after Q4 2018
Regenxbio Inc
Topline data from RGX-501 Phase I/II clinical trial
Homozygous Familial Hypercholesterolemia (HoFH)
after Q4 2018
uniQure N.V.
Data from dose confirmation study of AMT-061
Hemophilia B
after Q4 2018
Eli Lilly And Co.
PFS data readout from ongoing Phase 3 study of CYRAMZA
EGFR-positive non-small cell lung cancer
after Q4 2018
TYME TECHNOLOGIES, INC.
Interim data from phase II trial of SM-88
metastatic pancreatic cancer
after Q4 2018
TYME TECHNOLOGIES, INC.
Initial results from first stage of Phase II clinical trial of SM-88
Metastatic pancreatic cancer
after Q4 2018
TYME TECHNOLOGIES, INC.
Additional data from ongoing Phase II clinical trial of SM-88
Prostate cancer